Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
Fiscal Q4 Ending 12/11 |
|
Sales/Revenue |
37,161 | 64,798 | 42,912 | 36,825 | 14,941 |
Cost of Goods Sold (COGS) incl. D&A |
655 | NA | 19,966 | 18,190 | NA |
COGS excluding D&A |
0 | NA | 19,833 | 18,073 | NA |
Depreciation & Amortization Expense |
655 | 709 | 133 | 117 | 106 |
Gross Income |
36,506 | NA | 22,946 | 18,635 | NA |
SG&A Expense |
63,261 | 61,181 | 22,821 | 17,527 | 26,834 |
Research & Development |
22,003 | 32,045 | 1,584 | 1,840 | 17,969 |
Other SG&A |
41,258 | 29,136 | 21,237 | 15,687 | 8,865 |
Other Operating Expense |
0 | 0 | 0 | 0 | 0 |
Unusual Expense |
0 | 2,500 | 1,100 | NA | 0 |
Non Operating Income/Expense |
-111 | -154 | 83 | -98 | 59 |
Equity in Affiliates (Pretax) |
NA | 0 | 0 | 0 | 0 |
Interest Expense |
4,872 | 4,840 | 4,688 | 585 | 0 |
Gross Interest Expense |
4,872 | 4,840 | 4,688 | 585 | 0 |
Pretax Income |
-31,649 | -4,529 | -5,524 | 452 | -11,940 |
Income Tax |
11 | 8 | -24 | 12 | -1,069 |
Equity in Affiliates |
0 | 0 | 0 | 0 | 0 |
Consolidated Net Income |
-31,660 | -4,537 | -5,500 | 440 | -10,871 |
Minority Interest Expense |
0 | 0 | 0 | 0 | 0 |
Net Income |
-31,660 | -4,537 | -5,500 | 440 | -10,871 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | 0 | NA | 0 |
Net Income After Extraordinaries |
-31,660 | -4,537 | -5,500 | 440 | -10,871 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
-31,660 | -4,537 | -5,500 | 440 | -10,871 |
Operational EPS |
-0.43 | -0.04 | -0.06 | 0.01 | -0.16 |
EPS (basic) |
-0.43 | -0.06 | -0.08 | 0.01 | -0.16 |
EBITDA |
-26,100 | 3,617 | 258 | 1,225 | -11,893 |
Depreciation & Amortization Expense |
655 | 709 | 133 | 117 | 106 |
Common Shares Outstanding |
73,627 | 73,697 | 72,770 | 77,299 | 69,920 |
Basic Shares Outstanding |
73,627 | 73,697 | 72,770 | 71,907 | 69,920 |
Diluted Shares Outstanding |
73,627 | 73,697 | 72,770 | 77,299 | 69,920 |
Diluted EPS after Extraordinary Items |
-0.43 | -0.06 | -0.08 | 0.01 | -0.16 |
Discont. Operations Per Share |
0 | 0 | 0 | 0 | 0 |
Continued operations EPS |
-0.43 | -0.06 | -0.08 | 0.01 | -0.16 |
*Figures in thousands of U.S. Dollars except shares outstanding.
